Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation

被引:28
作者
Sembera, Stepan [1 ]
Lammert, Craig [1 ]
Talwalkar, Jayant A. [1 ]
Sanderson, Schuyler O. [1 ]
Poterucha, John J. [1 ]
Hay, J. Eileen [1 ]
Wiesner, Russell H. [1 ]
Gores, Gregory J. [1 ]
Rosen, Charles B. [1 ]
Heimbach, Julie K. [1 ]
Charlton, Michael R. [1 ]
机构
[1] Mayo Clin, William J von Leibig Transplant Ctr, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
TRIMETHOPRIM-SULFAMETHOXAZOLE; INTRAHEPATIC CHOLESTASIS; CENTRILOBULAR NECROSIS; RISK-FACTORS; HEPATOTOXICITY; ASSOCIATION; REJECTION; IMPACT;
D O I
10.1002/lt.23424
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Drug-induced liver injury (DILI) is increasingly being recognized as a common cause of acute hepatitis. The clinical impact of DILI after liver transplantation (LT) is not known. The aim of this study was to describe the frequency, clinical presentation, and outcomes of DILI in LT recipients. LT recipients with possible DILI were identified with electronic pathology records and clinical note database retrieval tools. Diagnostic criteria were applied to identify cases of DILI. Twenty-nine of 1689 LT recipients (1.7%) were identified with DILI. The mean age was 52 years, and 52% were women. The major indications for LT were primary sclerosing cholangitis (28%), cholangiocarcinoma (14%), and hepatocellular carcinoma (14%). The severity of DILI was mild or moderate in 92% of the cases. Nausea or diarrhea (31%), jaundice (24%), and pruritus (10%) were the most common symptoms at the time of diagnosis. The mean biochemistry values were as follows: alanine aminotransferase, 204 +/- 263 U/L; aspartate aminotransferase, 108 +/- 237 U/L; alkaline phosphatase, 469 +/- 689 U/L; and total bilirubin, 1.9 +/- 10.3 mg/dL. The median duration of medication use until the diagnosis of DILI was 57 days, and the major agent classes were antibiotics (48%), immunosuppressive agents (14%), and antihyperlipidemic drugs (7%). Trimethoprim-sulfamethoxazole was the most common implicated agent (n = 11). Serum liver enzymes improved within a median time of 34 days (range = 5-246 days) after drug withdrawal. Hepatic retransplantation or death did not occur. Among the 50 cases with possible DILI explained by other causes, 13 individuals (26%) had no alternative diagnosis despite histological findings compatible with DILI. In conclusion, DILI is a rare yet underrecognized event among LT recipients. The majority of cases are not clinically severe, and they resolve after drug cessation without hepatic retransplantation or death. Liver Transpl, 2012. (C) 2012 AASLD.
引用
收藏
页码:803 / 810
页数:8
相关论文
共 27 条
[1]   Important Elements for the Diagnosis of Drug-Induced Liver Injury [J].
Agarwal, Vijay K. ;
McHutchison, John G. ;
Hoofnagle, Jay H. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (05) :463-470
[2]   Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period [J].
Andrade, RJ ;
Lucena, MI ;
Fernández, MC ;
Pelaez, G ;
Pachkoria, K ;
García-Ruiz, E ;
García-Munoz, B ;
González-Grande, R ;
Pizarro, A ;
Durán, JA ;
Jiménez, M ;
Rodrigo, L ;
Romero-Gomez, M ;
Navarro, JM ;
Planas, R ;
Costa, J ;
Borras, A ;
Soler, A ;
Salmerón, J ;
Martin-Vivaldi, R .
GASTROENTEROLOGY, 2005, 129 (02) :512-521
[3]   Intrahepatic cholestasis after liver transplantation [J].
Ben-Ari, Z ;
Pappo, O ;
Mor, E .
LIVER TRANSPLANTATION, 2003, 9 (10) :1005-1018
[4]   Review article: drug-induced liver injury in clinical practice [J].
Bjornsson, E. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (01) :3-13
[5]   ACUTE-LIVER-DISEASE ASSOCIATED WITH ERYTHROMYCINS, SULFONAMIDES, AND TETRACYCLINES [J].
CARSON, JL ;
STROM, BL ;
DUFF, A ;
GUPTA, A ;
SHAW, M ;
LUNDIN, FE ;
DAS, K .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (07) :576-583
[6]   Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-induced Liver Injury in the United States [J].
Chalasani, Naga ;
Fontana, Robert J. ;
Bonkovsky, Herbert L. ;
Watkins, Paul B. ;
Davern, Timothy ;
Serrano, Jose ;
Yang, Hongqiu ;
Rochon, James .
GASTROENTEROLOGY, 2008, 135 (06) :1924-1934
[7]   Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation [J].
Charatcharoenwitthaya, Phunchai ;
Pimentel, Sylvania ;
Talwalkar, Jayant A. ;
Enders, Felicity T. ;
Lindor, Keith D. ;
Krorn, Ruud A. F. ;
Wiesner, Russell H. .
LIVER TRANSPLANTATION, 2007, 13 (09) :1236-1245
[8]   CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS .1. A NOVEL METHOD BASED ON THE CONCLUSIONS OF INTERNATIONAL CONSENSUS MEETINGS - APPLICATION TO DRUG-INDUCED LIVER INJURIES [J].
DANAN, G ;
BENICHOU, C .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (11) :1323-1330
[9]   Drug-Induced Liver Injury Network (DILIN) Prospective Study Rationale, Design and Conduct [J].
Fontana, Robert J. ;
Watkins, Paul B. ;
Bonkovsky, Herbert L. ;
Chalasani, Naga ;
Davern, Timothy ;
Serrano, Jose ;
Rochon, James .
DRUG SAFETY, 2009, 32 (01) :55-68
[10]   NODULAR REGENERATIVE HYPERPLASIA OF THE LIVER GRAFT AFTER LIVER-TRANSPLANTATION [J].
GANE, E ;
PORTMANN, B ;
SAXENA, R ;
WONG, P ;
RAMAGE, J ;
WILLIAMS, R .
HEPATOLOGY, 1994, 20 (01) :88-94